AI Verdict
IMAX has stronger fundamentals based on our AI analysis.
IMCR vs IMAX Fundamental Comparison
| Metric | IMCR | IMAX |
|---|---|---|
| Revenue | $400.0M | $410.2M |
| Net Income | $-35.5M | $34.9M |
| Net Margin | -8.9% | 8.5% |
| ROE | -9.3% | 10.3% |
| ROA | -3.3% | 3.9% |
| Current Ratio | 4.04x | N/A |
| Debt/Equity | 1.15x | 0.00x |
| EPS | $-0.71 | $0.63 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IMCR vs IMAX: Frequently Asked Questions
Is IMCR or IMAX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IMAX has stronger fundamentals. IMCR is rated HOLD (65% confidence) while IMAX is rated HOLD (78% confidence). This is not investment advice.
How does IMCR compare to IMAX fundamentally?
Immunocore Holdings plc has ROE of -9.3% vs IMAX CORP's 10.3%. Net margins are -8.9% vs 8.5% respectively.
Which stock pays higher dividends, IMCR or IMAX?
IMCR has a dividend yield of N/A or no dividend while IMAX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IMCR or IMAX for long term?
For long-term investing, consider that IMCR has HOLD rating with 65% confidence, while IMAX has HOLD rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IMCR vs IMAX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IMCR vs IMAX, the AI consensus favors IMAX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.